Authored Content
A detailed Avalere report offers insights into state-specific statutes guiding commercial payer coverage for off-label use of oncology drugs/biologics.
Avalere’s report, updated semi-annually, is available now with insights into state policies on point-of-service substitution of biosimilar products.
Recent FDA authorization of Florida’s Section 804 Importation Program has prompted increased focus on importation pathways.
Receiving a complete response letter is not a rejection, but it introduces important business questions for product launch planning.